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Bovine insulin was glycated under hyperglycemic reducing conditions and in nonreducing
conditions. Purification through HPLC allowed isolating glycated forms of insulin and a novel
triglycated form (6224.5 Da) was purified. Endoproteinase Glu-C digestion combined with
mass spectrometry (MALDI-TOF/TOF) allowed determining the exact location of the glyca-
tion sites in each of the isolated glycated insulins. For the first time, a triglycated form of
insulin was isolated and characterized accordingly to its glycation sites. These glucose binding
sites were identified as the N-terminals of both chains (Gly1 and Phe1) and residue Lys29 of
B-chain. Moreover, in diglycated insulin we found the coexistence of one specie glycated at the
N-terminals of both chains (Gly1 and Phe1) and another specie containing the two glucitol
adducts in B-chain (Phe1 and Lys29). Also, in monoglycated insulin generated in reducing and
nonreducing conditions, one specie glycated at Phe1 and another specie glycated at Lys29,
both B-chain residues coexist. (J Am Soc Mass Spectrom 2009, 20, 1319–1326) © 2009
American Society for Mass SpectrometryOver the last years, particular attention has beengiven to the role of nonenzymatic glycation indiabetic complications development, including
neuropathy, nephropathy, retinopathy, and cardiovascu-
lar disease [1]. Under conditions of hyperglycemia, glyca-
tion compromises several functional proteins, such as
hemoglobin [2, 3], glucose-6-phosphate dehydrogenase
[4, 5], aldehyde reductase [6], glutathione reductase [7,
8], glutathione peroxidase [8, 9], and Cu-Zn superoxide
dismutase [10, 11]. In this context, insulin glycation is of
particular interest. The structurally modified peptide
exhibits decreased ability to regulate plasma glucose
homeostasis and is associated with reduced hepatic
clearance, decreased adipose tissue lipogenesis, and a
decreased glucose uptake and oxidation in isolated
diaphragm and abdominal muscle in vitro [12–15].
Even though the short half-life of insulin (5–10 min),
experiments performed to date indicate that a substan-
tial proportion of insulin (and proinsulin) is glycated in
the pancreatic cells during the stages of insulin synthe-
sis and storage [16]. Glycated insulin has been mea-
sured in the pancreas of various animal models of type
2 diabetes [17], and in both isolated islets and clonal
-cells exposed to elevated glucose concentrations in
tissue culture [18, 19]. The significant compromised
biological activity of glycated insulin raises the possi-
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cose intolerance of type 2 diabetes.
Earlier studies indicated that during glycation pro-
cess, each insulin molecule can bind to three to eight
molecules of glucose [14, 20]. More recently, indepen-
dent reports generalized the view that there are three
possible free amino groups in the insulin molecule,
human or bovine, available for in vitro glucose binding
[15, 21–23]. Nowadays, through ESI-MS/MS and
MALDI-MS approaches, it is established the N-terminal
Phe1 residue of the B-chain is the only glycation site of
human [23] and bovine [21] insulin. Moreover, O’Harte
and coworkers determined, in a novel diglycated insu-
lin (under hyperglycemic reducing conditions), the N-
terminals Gly1 of A-chain and Phe1 of B-chain as the
sites of glycation for human insulin [15], after Glu-C
enzymatic digestion and identification of digested frag-
ments by plasma desorption mass spectrometry (PDMS).
Since human and bovine insulin only differ in three
residues (A chain: residues 8 and 10; B chain: residue
30), it is expected that glycation of bovine insulin
should occur in similar positions.
The present study structurally characterizes three
forms of glycated bovine insulin when glycated under
reducing conditions. Simultaneously, the characteriza-
tion of glycated insulin produced under pseudophysi-
ological conditions was also done. Our approach in-
cluded HPLC purification of mono-, di-, and triglycated
insulin forms, followed by enzymatic digestion and
mass spectrometry (MALDI-TOF/TOF) for the unam-
biguous assignment of the glycation sites.
Published online March 13, 2009
r Inc. Received December 2, 2008
Revised February 2, 2009
Accepted March 5, 2009
1320 GUEDES ET AL. J Am Soc Mass Spectrom 2009, 20, 1319–1326Materials and Methods
Chemicals and Reagents
Bovine insulin (I5500) and TFA were acquired from
Sigma (St. Louis, MO). The MALDI matrices -cyano-
4-hydroxy cinnamic acid (CHCA) and sinapinic acid
were supplied by Merck (Darmstadt, Germany). The
organic solvents such as toluene and acetonitrile (ACN)
were from Riedel-deHaën (Buchs, Switzerland) and
Labscan (Dublin, Ireland), respectively.
All chemicals were of analytical grade and milli-Q
water (Millipore, Bedford, MA) was used throughout
all experiments.
Insulin In Vitro Glycation
In vitro glycation was carried out by incubating insulin
with D-glucose in a protocol adapted from O’Harte et
al. where reducing [23] and nonreducing conditions
were used. In nonreducing conditions, insulin (200 g
in HCl 2 mM) was incubated with D-glucose 220 mM in
phosphate buffer 10 mM (pH 7.4) at 37 °C for 30 d
(toluene 5 mM was added as a bacteriostatic). In reduc-
ing conditions and according to the authors, insulin
(100 g in HCl 2 mM) was incubated for 24 h at 37 °C
with D-glucose 220 mM (prepared in phosphate buffer
10 mM, pH 7.4) together with a 1000-fold molar excess
of the reducing agent NaBH3CN (stock in ice cold
NaOH 10 mM) in phosphate buffer 10 mM (pH 7.4). In
both cases, after incubation, reaction was stopped by
addition of acetic acid 0.5 M, and the reaction mixture
was dialyzed overnight against water (cut-off 1000 Da).
Glycated and native forms were separated on a C-8
analytical column (Acclaim, 4.6  250 mm, 5 m particle
size; Dionex, Sunnyvale, CA) at a flow rate of 0.8mL/min.
The program was as follows: linear gradient of 0% to 35%
ACN over 10 min, followed by 35% to 56% ACN over 20
min, and 56% to 70% ACN over 5 min. Peaks were
hand-collected, pooled from several runs, and concen-
trated on a Speed-vac. Re-injection of each glycated
form using the same separation program allowed to
improve the purification of each glycated insulin form.
This purification was monitored through MALDI-MS.
Enzymatic Digestion (Endoproteinase Glu-C)
For in-solution digestion of glycated and native insulin,
samples were initially reconstituted in HCl 2 mM.
Quantification was performed using the Quant-iT Pro-
tein Assay kit (Invitrogen, Paisley, UK) combined with
the Qubit fluorometer. An aliquot was taken and diluted
for enzymatic digestion with phosphate buffer 10 mM pH
7.8; pH is determinant since the specificity of endoprotein-
ase Glu-C for glutamic acid depends on this parameter.
Endoproteinase Glu-C (Calbiochem, Merck, Darmstadt,
Germany) solution was added in a final ratio of substrate:
enzyme of 20:1 (wt/wt). Duplicate samples were incu-
bated overnight at 25 °C. After digestion, samples weredried under vacuum in a Speed-vac and, unless taken for
analysis, stored at 80 °C.
Reduction of Disulphide Bridges of Insulin
The disulphide bridges of monoglycated, diglycated,
triglycated, and native insulin were reduced using DTT
10 mM in phosphate buffer pH 8 for 1 h at 55 °C. An
aliquot of each sample (10 L) was taken and acidified
with TFA 1% (1 L). These aliquots were cleaned up
using ZipTip C18 (Millipore, Bedford, MA) before mass
spectrometry analysis.
Mass Spectrometry
Glu-C digests of glycated and native insulin were recon-
stituted in TFA 0.1%. An aliquot of each sample was
mixed (1:1) with -CHCA matrix solution (5 mg/mL in
ACN 50%/TFA 0.1%) and applied onto 384-well MALDI
plates. Instrument was calibrated by adding insulin (12.5
ng; 0.5 L) to each calibration spot. Peptide mass spectra
were obtained with a MALDI-TOF/TOF mass spectrom-
eter (4800 Proteomics Analyzer; Applied Biosystems, Fos-
ter City, CA) in the positive ion reflector mode. Spectra
were obtained in the mass range between 800 and 7000
Da. Manual interpretation of tandem mass spectra was
performed through the Data Explorer software TM ver.
4.4 (Applied Biosystems).
Results and Discussion
Glycation of insulin was monitored by MALDI-MS
through the increase in the molecular weight of insulin
as a result of glucose adducts formation with the
hormone. Figure 1 shows the typical mass spectra of
native (a) and glycated insulin (b and c). In Figure 1b,
we can observe a typical spectrum of glycated insulin
where glycation of the hormone was performed by
incubation with 220 mM glucose for 30 d at 37 °C in the
absence of reducing conditions. The major peak at m/z
5730.66 corresponds to native bovine insulin (theoreti-
cal m/z 5730.6) whereas the second peak at m/z 5892.72
with a mass shift of 162 Da corresponds to a monogly-
cated form of insulin. A third minor peak at m/z 6054.71
is also observable and should correspond to a digly-
cated form with a mass shift of 324 Da. Figure 1c, where
insulin glycation was performed by incubation with 220
mM glucose for 30 h at 37 °C in reducing conditions
(NaBH3CN), shows a different mass profile, especially
in terms of relative abundance of each specie. There are
three additional peaks in the spectrum besides the peak
corresponding to native insulin. The major peak, at m/z
of 5894.72, is the protonated monoglycated form with a
mass shift of 164 Da (glucitol adduct). The two other
peaks at m/z 6058.89 and 6222.82 correspond to the
protonated diglycated and triglycated forms, respec-
tively. With the mono-, di-, and triglycated forms,
several additional peaks are observed. These peaks are
BH3-adducts (m  14 Da), resulting from the in vitro
1321J Am Soc Mass Spectrom 2009, 20, 1319–1326 TANDEM MS OF GLYCATED INSULINglycation procedure where an excess of this reducing
agent is used.
After separating the different glycated forms of in-
Figure 1. Typical MALDI-MS spectra of nativ
nonreducing conditions. (a) Native insulin, (b
(c) glycated insulin under reducing conditions.sulin by HPLC-C8, purified samples were reconstitutedin HCl 2 mM and quantified with Quant-iT Protein
Assay kit. In the absence of reducing conditions, 32% of
the purified monoglycated form was obtained. In re-
lin and glycated insulin in both reducing and
cated insulin under nonreducing conditions,e insu
) glyducing conditions 45% of monoglycated, 25% of di-
1322 GUEDES ET AL. J Am Soc Mass Spectrom 2009, 20, 1319–1326glycated, and 6% of triglycated forms of insulin were
obtained.
To identify the glycation sites, each sample was
enzymatically digested with endoproteinase Glu-C as
described in the experimental section. Cleavage of insulin
at glutamic acid residues without disulfide bridges dis-
ruption theoretically produces nine fragments (Table 1).
Digested samples of glycated and native insulin were
analyzed by MALDI-MS, and Figure 2 shows represen-
tative spectrum of Glu-C digests for all studied sam-
ples. Highlighted peaks that are present solely in gly-
cated samples were chosen for analysis through tandem
mass spectrometry (MALDI-MS/MS). Table 1 shows
the identified peaks in all samples. Figure 3 shows the
two MS/MS spectra of the peptides at m/z 1248.57
(Figure 3a) and 1644.68 (Figure 3b), identified as frag-
ments B1-13 and B22-30 from glycated insulin (no
Table 1. Theoretical peptide fragments from endoproteinase Glu
obtained from Glu-C digests of glycated insulin samples. Underli
Position Peptide s
Native insulin
A 1-4 GIVE
A 5-17 QCCASVCSLYQLE
A 5-17 QCCASVCSLYQLE
A 18-21 NYCN
B 1-13 FVNQHLCGSHLVE
B 14-21 ALYLVCGE
B 22-30 RGFFYTPKA
A 5-17/B 1-13 QCCASVCSLYQLE/F
A 18-21/B 14-21 NYCN/ALYLVCGE
Glycated insulin
Monoglycated insulin (nonreducing
conditions)
B 14-21 ALYLVCGE
B 22-30 RGFFYTPKA
B 22-30 RGFFYTPKA
A 18-21/B 14-21 NYCN/ALYLVCGE
A 5-17 QCCASVCSLYQLE
B 1-13 FVNQHLCGSHLVE
B 1-13 FVNQHLCGSHLVE
Glycated insulin (reducing conditions)
Monoglycated
B 22-30 RGFFYTPKA
B 22-30 RGFFYTPKA
A 18-21/B 14-21 NYCN/ALYLVCGE
A 5-17 QCCASVCSLYQLE
B 1-13 FVNQHLCGSHLVE
Diglycated
B 22-30 RGFFYTPKA
B 22-30 RGFFYTPKA
A 18-21/B 14-21 NYCN/ALYLVCGE
A 5-17 QCCASVCSLYQLE
B 1-13 FVNQHLCGSHLVE
A 1-21 GIVEQCCASVCSLY
Triglycated
B 22-30 RGFFYTPKA
B 22-30 RGFFYTPKA
A 18-21/B 14-21 NYCN/ALYLVCGE
A 5-17 QCCASVCSLYQLE
B 1-13 FVNQHLCGSHLVE
A 1-21 GIVEQCCASVCSLYQLENreducing conditions) with one glucose adduct attached
(see Table 1).
Analysis of the MS/MS spectrum of the modified
peptide at m/z 1248.57 (Figure 3a) allows locating the
glucose adduct in residue Lys29. In the MS/MS spec-
trum, it is possible to see the mass difference of 290.2 Da
between the ion at m/z 1131.5 (a8) and the ion at m/z
841.3 (a7). This gap corresponds to the loss of the lysine
residue with a glucose adduct. Analysis of the MS/MS
spectrum of the precursor ion at 1644.68 (see Figure 3b)
allows locating the glucose adduct in residue Phe1.
These results agree with the literature [21, 22], which
state the most likely sites of glycation within the B-chain
are the Phe1 and Lys29 residues, as both contain free
amino groups for linking glucose molecules. Neverthe-
less, the preferred glycation site of monoglycated bo-
vine or human insulin is thought to be at Phe-1 of the
igestion of native insulin and experimental glycated fragments
residues correspond to cysteines involved in disulfide bridges
nce
Theoretical
mass (Da)
Experimental
mass (Da)
Match
error (Da)
417.2324 — —
1446.6062 — —
1444.5906 1444.4225 0.1681
513.1762 — —
1482.7158 1482.6351 0.0807
867.4280 867.4041 0.0239
1086.5731 1086.5048 0.0683
HLCGSHLVE 2924.283 — —
1377.5808 1377.4717 0.1091
867.4280 867.4378 0.0098
1086.5731 1086.5291 0.0440
1248.6259 1248.5710 0.0549
1377.5808 1377.5029 0.0779
1444.5906 1444.5505 0.0401
1482.7158 1482.6345 0.0813
1644.7686 1644.6820 0.0866
1086.5731 1086.4946 0.0785
1250.6415 1250.5546 0.0869
1377.5808 1377.4662 0.1146
1444.5906 1444.5294 0.0612
1646.7842 1646.6748 0.1094
1086.5731 1086.4970 0.0761
1250.6415 1250.5597 0.0818
1377.5808 1377.4740 0.1068
1444.5906 1444.5748 0.0158
1646.7842 1646.7093 0.0749
YCN 2501.0345 2501.0765 0.0420
1086.5731 1086.4949 0.0782
1250.6415 1250.5478 0.0937
1377.5808 1377.4398 0.1410
1444.5906 1444.5100 0.0806
1646.7842 1646.6378 0.1464-C d
ned
eque
VNQ
QLENYCN 2501.0345 2501.1065 0.0720
1323J Am Soc Mass Spectrom 2009, 20, 1319–1326 TANDEM MS OF GLYCATED INSULINB-chain [23]. This is most probably due to the high
reactivity as this residue is situated at the N-terminal of
the peptide chain. Herein, we show that monoglycated
insulin produced in the absence of reducing conditions
comprises the coexistence of two glycated insulin spe-
cies with two different glycation sites, Phe1 or Lys29.
Figure 4 shows three representative examples of
MS/MS spectra of glycated fragments belonging to gl-
ycated insulin produced under reducing conditions.
The two glycated fragments that result from Glu-C
digestion are the peptides at m/z 1250.56 and m/z
1646.67, and were found in all of three forms of glycated
insulin (see Figure 2). These peptides were fragments
B1-13 and B22-30 with identical glycation sites, Phe1
and Lys29, respectively, as reported for the monogly-
cated insulin formed in the absence of reducing condi-
tions. In this case, because of the excess of reducing
agent (NaBH3CN), the mass shift found in the MS/MS
spectra corresponds to the attachment of a glucitol
adduct (164 Da). Again, the coexistence of two glycated
forms occurs in monoglycated insulin produced under
reducing conditions.
With the approach described so far, it was not
Figure 2. MALDI-MS spectra of Glu-C digests o
for both glycation procedures. The m/z values o
shown in Table 1 are highlighted with rectan
glycated samples are unique to these samples
insulin, (b) monoglycated insulin under nonre
reducing conditions, (d) diglycated insulin (red
conditions).possible to identify any glycated fragments belongingto the A-chain in monoglycated, diglycated and trigly-
cated forms of insulin. To induce the separation of the
two chains (A and B) of the insulin samples, the
disulphide bridges were reduced with DTT using an
aliquot of undigested samples, as described in the
Experimental section. These reduced samples were sub-
mitted to MALDI-MS and MALDI-MS/MS analysis.
Figure 4c shows the representative MS/MS spectrum of
the A-chain containing a single glucitol adduct, with an
m/z 2501, which was found only in diglycated and
triglycated forms of insulin. The identification of the
complete b series allowed the identification of Gly1 as
the glycation site in the A-chain. This result allowed
determining the three sites of glycation in triglycated
insulin and also pointed out the presence of two iso-
forms in diglycated insulin, similar to the monoglycated
forms of insulin. Therefore, in diglycated insulin, there
is the coexistence of one specie glycated at the N-
terminals of both chains (Gly1 and Phe1) and another
specie containing the two glucitol adducts in chain B
(Phe1 and Lys29).
Furthermore, we calculated the relative abundance
(RA), in percentage, of glycated peptides for monogly-
ive insulin and isolated forms of glycated insulin
gments matching theoretical peptide fragments
Peptide fragments highlighted with circles in
correspond to glycated fragments. (a) Native
g conditions, (c) monoglycated insulin under
g conditions), (e) triglycated insulin (reducingf nat
f fra
gles.
and
ducin
ucincated and diglycated samples. As normalizing reference
ducin
1324 GUEDES ET AL. J Am Soc Mass Spectrom 2009, 20, 1319–1326peak, we used the peak at m/z 1086 (chain B residues
22–30) since it is the most abundant peak in GluC-
digested samples. This analysis indicate that the mono-
glycated insulin of Figure 1b is preferably glycated at
Lys29 (Lys29 RA  30.7%  0.8%; Phe-1 RA  5.7% 
0.5%), while in the monoglycated insulin of Figure 1c, the
two possible glycation sites present a similar abundance
(Lys29 RA  6.0%  0.1%; Phe1 RA  5.1%  1.3%). In
the case of diglycated insulin from Figure 1c, although
also glycated at Gly1 of chain A, data indicate it appears to
be preferably glycated at Lys29 (Lys29 RA  23.5% 
0.3%; Phe1 RA 4.6% 0.7%). Therefore, this diglycated
form appears to coexist in two isoforms, one glycated at
Phe1 and Lys29 of chain B and the other glycated at Lys29
Figure 3. MS/MS spectra of the modified pept
between B 22–30 with a glucose adduct located
(b), corresponding to the sequence between B 1–
in monoglycated insulin produced under nonre(chain B) and Gly1 (chain A).This is the first time that a triglycated form of insulin
was isolated and characterized according to its glycation
sites. In addition, we were also able to identify in digly-
cated insulin, the simultaneous presence of two isoforms
where three sites of glycation are possible, rather than
solely the N-terminals of both chains (Gly1 and Phe1), as
reported for human insulin [15]. Therefore, the impor-
tance of Lys29 as a possible site of glycation occurring in
vivo should not be ignored, as also shown by the results
corresponding to the monoglycated insulin produced in
nonreducing conditions. To date, the impairment of in
vivo and in vitro actions of insulin when glycated has only
been studied with insulin glycated under reducing condi-
tions [12, 13, 15], and therefore only considered to be
t m/z 1248.57 (a), corresponding to the sequence
ys29, and the modified peptide at m/z 1644.68
cated at Phe1. These glycation sites were found
g conditions.ide a
at L
13 glyglycated at the N-terminal Phe1 of the B-chain [13] or
1325J Am Soc Mass Spectrom 2009, 20, 1319–1326 TANDEM MS OF GLYCATED INSULINglycated at theN-terminals of both chains (Gly1 and Phe1)
[15]. It would be of interest to develop further work with
glycated insulin at Lys29, since insulin glycation in vivo is
associated with characteristic complications of type 2
diabetes such as glucose intolerance and insulin resis-
tance. Elucidating the importance of the structural alter-
ations, which occur in consequence of glycation, in the
modulation of insulin action should continue to be of
great interest.
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